Figure 3.

MaR1 is a potent anti-inflammatory and proresolving mediator. A) Murine peritonitis. Zymosan (0.1 mg) was administered to mice (see Materials and Methods) 10 min after i.v. MaR1. After 4 h, peritonea were lavaged, and the total numbers of leukocytes, PMNs, and mononuclear cells along with the number of Ly6G-positive cells were determined (n=4 mice/group). *P < 0.05 vs. vehicle group. B) MΦ efferocytosis of apoptotic PMNs. MΦs (24-well plate, 10⁵ cells/well) were exposed to either MaR1, RvD1, or LTB₄ mediators at 1 nM (37°C, 15 min) followed by CFDA-labeled apoptotic human PMNs (90 min, 37°C). Results are expressed as percentage increase above vehicle (n=3). *P ≤ 0.05, **P ≤ 0.01 vs. vehicle; ^#P ≤ 0.05, ^##P ≤ 0.01 vs. LTB₄. C) MaR1 enhances efferocytosis: Apoptotic neutrophils prelabeled with CFDA were coincubated in the presence of vehicle or the indicated amounts of MaR1, 7S isomer I, or 12E isomer II (1 h at 37°C) in 5% CO₂. Nonphagocytosed cells were washed, and the extent of phagocytosis was determined (see Materials and Methods; n=3–4 separate donors). Results are means ± se.